Mean values in RLS severity (IRLS), quality of life (SF-36), depression (CES-D) and sleep (PSQI) scales at baseline 12-months, 24-months and 36-months follow-up.

a<p>p-value for difference between assessments according to one-way repeated measures ANOVA.</p

Figure 2

<p>A) Short term variation of the RLS minimal criterion “urge to move” in the 7-day diary, according to IRLS^a score and time of the day. B) Short term variation of the RLS minimal criterion “dysaesthesia” in the 7-day diary according IRLS^a score and time of the day.</p

Mean IRLS^a score according to six age groups at baseline, 6-, 12- 24- and 36-months follow-up.

<p>Mean IRLS^a score according to six age groups at baseline, 6-, 12- 24- and 36-months follow-up.</p

Clinical characteristics and differences in health status according to changes in RLS severity (IRLS^c) over 36 months.

<p>*p for differences between the 3 groups derived from one-way analysis of variance (ANOVA) unless otherwise noted.</p>a<p>Chi-square test for the difference between gender.</p>b<p>Change in the International Restless Legs Study Group (IRLSSG) Rating Scale for severity of RLS between baseline and 36 months follow-up: worsening = increase in score by >5 points, unchanged = change in score not more than ±5 points, improving =  decrease in score >5 points.</p>c<p>International Restless Legs Study Group Rating Scale for severity of RLS (IRLS).</p

Characteristics of the COR-Study participants at baseline.

a<p>based on self-reported weight and height.</p>b<p>self-reported physician diagnosis.</p

Tumor formation after subcutaneous inoculation of ES or <i>in vitro</i> differentiated cells into various hosts.

<p>ES cells and cells differentiated <i>in vitro</i> for 14 days were injected subcutaneously into the flank of syngeneic or allogeneic mice or xenogeneic rats (1×10⁶ cells in PBS/animal). Some recipients received an immunosuppressive treatment with CsA (10 mg/kg/day). The percentage and number of animals in which tumors were found during autopsy or in which tumors were palpable (at least during 3 consecutive observations) at the side of injection before day 100 after injection is indicated.</p>1<p>in 2 mice (8%) a tumor regression was observed before day 100.</p>2<p>in 2 mice (9%) a tumor regression was observed before day 100.</p>3<p>in 1 mouse (7%) a tumor regression was observed before day 100.</p>4<p>in 2 mice (11%) a tumor regression was observed before day 100.</p>5<p>in 8 female mice (47%) a tumor regression was observed before day 100.</p>6<p>in 2 rats (11%) a tumor regression was observed before day 100.</p

Analysis of effects of NK cells on the rejection of ES cells in vivo.

<p>(A) 1×10⁶ ES cells were injected subcutaneously at day 0 into 15 T and B cell deficient SCID mice which have functional NK cells. The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in individual mice is shown. Tumor growth in female hosts is indicated by red lines and in male hosts by blue lines. In one animal a tumor regression was observed. (B) The treatment scheme of rats receiving an NK cells depleting antibody (anti-NKR-P1A) or an isotype control is shown. (C) The mean proportion plus SD of NK cells in the blood of male LOU rats receiving the anti-NKR-P1A mAb (n = 8) or the isotype control (n = 6) is shown. Blood cells were stained with the respective mAb and analyzed by flow cytometry after lysis of erythrocytes. (D) The proportion of the male rats in which tumors were found at autopsy is indicated. The size of the tumors was 12 mm³ and 16 mm³, respectively. Both were palpable for more than 30 days before autopsy.</p

Tumor growth in syngeneic 129Sv and immunodeficient SCID/beige mice after injection of ES cells or <i>in vitro</i> differentiated cells.

<p>(A) 1×10⁶ ES cells (MPI-II) or <i>in vitro</i> differentiated cells (day 14 of differentiation culture) were injected subcutaneously at day 0 into syngeneic 129Sv mice (for the numbers of animals see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002622#pone-0002622-t002" target="_blank">Table 2</a>). The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in individual mice is shown. Tumor growth in female hosts is indicated by red and in male hosts by blue lines. (B) 1×10⁶ ES cells or <i>in vitro</i> differentiated cells were injected subcutaneously at day 0 into immunodeficient SCID/beige mice which are deficient for T, B, and functional NK cells.</p

Tumor formation after subcutaneous inoculation of various numbers of ES cells or <i>in vitro</i> differentiated cells in 129Sv mice.

<p>The indicated number of ES cells and cells differentiated <i>in vitro</i> for 14 days were injected subcutaneously into the flank of 129Sv mice. The percentage and number of animals is indicated in which tumors were found during autopsy at the side of injection before day 100 after injection.</p

Lysis of ES and <i>in vitro</i> differentiated cells by splenocytes derived from rats 6 weeks after intracerebral grafting of <i>in vitro</i> differentiated cells.

<p>Mean of specific lysis and SD of triplicates of ES cells (A, C, E, G) or <i>in vitro</i> differentiated cells (B, D, F) at three effector∶target (E∶T) ratios. Effector cells were lymphocytes obtained by density gradient centrifugation on Biocoll from spleens of grafted (no. 113–117) or naïve (co1 and co2) DA rats (A, B), grafted (no. 118–122) or naïve (co1 and co2) LEW.1N rats (C, D), and grafted Wistar rats (no. 38, 39, 48, 49, 51, 52, 53, 54, 56, 57). The individual rats are indicated by symbols. (G) Mean of specific lysis and SD of triplicates of ES cells by lymphokine-activated killer (LAK) cells derived from splenocytes of Wistar rats (no. 38, 48, 49, 51, 52, 54, 56) after culture for 4 days in the presence of 100 U/ml IL-2.</p